Treatment of diabetes with copper binding compounds

Details Treatment of diabetes with copper binding compounds Treatment of diabetes with copper binding compounds

2011-04-19

2011-04-19

Henley, III, Raymond J (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S400000, C514S561000, C514S674000

Reexamination Certificate

active

07928094

ABSTRACT:
Novel methods of treating a patient for diseases, disorders, and conditions including diabetes mellitus, comprising administering, for example, copper binding compounds.

REFERENCES:
patent: 3791988 (1974-02-01), Dieter
patent: 4323558 (1982-04-01), Nelson
patent: 4374829 (1983-02-01), Harris et al.
patent: 4410541 (1983-10-01), Kamimae et al.
patent: 4758583 (1988-07-01), Cerami et al.
patent: 4866090 (1989-09-01), Hoffman et al.
patent: 4952568 (1990-08-01), Sawai et al.
patent: 5077313 (1991-12-01), Lubec
patent: 5128360 (1992-07-01), Cerami et al.
patent: 5246970 (1993-09-01), Williamson et al.
patent: 5366505 (1994-11-01), Farber
patent: 5387109 (1995-02-01), Ishikawa et al.
patent: 5420120 (1995-05-01), Boltralik
patent: 5811446 (1998-09-01), Thomas
patent: 5824049 (1998-10-01), Ragheb et al.
patent: 5834032 (1998-11-01), Song
patent: 5852009 (1998-12-01), Cerami et al.
patent: 5854271 (1998-12-01), Thomas et al.
patent: 5906996 (1999-05-01), Murphy
patent: 5972985 (1999-10-01), Thomas et al.
patent: 5980914 (1999-11-01), Gerolymatos
patent: 6147070 (2000-11-01), Faccjomo
patent: 6309380 (2001-10-01), Larson et al.
patent: 6329414 (2001-12-01), Thomas et al.
patent: 6348465 (2002-02-01), Baker
patent: 6576672 (2003-06-01), Murphy
patent: 6610693 (2003-08-01), Baker
patent: 6821954 (2004-11-01), Reid et al.
patent: 6884575 (2005-04-01), Cooper et al.
patent: 6897243 (2005-05-01), Baker et al.
patent: 6951890 (2005-10-01), Cooper et al.
patent: 6855511 (2005-12-01), Baker et al.
patent: 7176239 (2007-02-01), Wang et al.
patent: 7189865 (2007-03-01), Ternansky et al.
patent: 7344887 (2008-03-01), Peled et al.
patent: 7365170 (2008-04-01), Cooper et al.
patent: 7459446 (2008-12-01), Baker et al.
patent: 2003/0013772 (2003-01-01), Murphy et al.
patent: 2003/0055003 (2003-03-01), Bar-Or et al.
patent: 2003/0055113 (2003-03-01), Wang et al.
patent: 2003/0139312 (2003-07-01), Caswell
patent: 2003/0166561 (2003-09-01), Cooper et al.
patent: 2003/0188946 (2003-10-01), Cooper et al.
patent: 2003/0232799 (2003-12-01), Wang et al.
patent: 2004/0003886 (2004-02-01), Cooper et al.
patent: 2004/0142393 (2004-07-01), Cooper et al.
patent: 2004/0259945 (2004-12-01), Brewer et al.
patent: 2005/0002876 (2005-01-01), Yukl et al.
patent: 2005/0031651 (2005-02-01), Gervais et al.
patent: 2005/0047998 (2005-03-01), Cooper et al. (Abandoned)
patent: 2005/0074756 (2005-04-01), Cooper et al.
patent: 2005/0085555 (2005-04-01), Murphy et al.
patent: 2005/0159364 (2005-07-01), Cooper et al.
patent: 30918/89 (1989-09-01), None
patent: 80936/94 (1995-05-01), None
patent: 14470/95 (1995-07-01), None
patent: 41349/96 (1996-05-01), None
patent: 3217071 (1983-11-01), None
patent: 0 331 014 (1989-02-01), None
patent: 0 426 066 (1991-05-01), None
patent: 0 576 838 (1994-01-01), None
patent: 1 234 858 (2002-08-01), None
patent: 2192789 (1988-01-01), None
patent: 2192790 (1988-01-01), None
patent: 57-144215 (1982-09-01), None
patent: 7118148 (1995-05-01), None
patent: 2000204037 (2000-07-01), None
patent: 202419 (1979-12-01), None
patent: WO 82-01804 (1982-05-01), None
patent: WO 85-04169 (1985-09-01), None
patent: WO 87-05505 (1987-09-01), None
patent: WO 95-11690 (1995-05-01), None
patent: WO 95-17900 (1995-07-01), None
patent: WO 96-12483 (1996-05-01), None
patent: WO 98-40071 (1998-09-01), None
patent: WO 99-45907 (1999-06-01), None
patent: WO 99-39712 (1999-08-01), None
patent: WO 00-18392 (2000-04-01), None
patent: WO 00-18891 (2000-04-01), None
patent: WO 00-78805 (2000-12-01), None
patent: WO 02-43722 (2002-06-01), None
patent: WO 02-079785 (2002-10-01), None
patent: WO 03-045424 (2003-06-01), None
patent: WO 03-062275 (2003-07-01), None
patent: WO 03-063880 (2003-08-01), None
patent: WO 03-074559 (2003-09-01), None
patent: WO 03-075910 (2003-09-01), None
patent: WO 03-077901 (2003-09-01), None
patent: WO 03-082259 (2003-10-01), None
patent: WO 03-093311 (2003-11-01), None
patent: WO 03-099223 (2003-12-01), None
patent: WO 2004-012760 (2004-02-01), None
patent: WO 2004-012761 (2004-02-01), None
patent: WO 2004-017956 (2004-03-01), None
patent: WO 2004-017957 (2004-03-01), None
patent: WO 2004-056861 (2004-07-01), None
patent: WO 2004-065614 (2004-08-01), None
patent: WO 2004-083215 (2004-09-01), None
patent: WO 2004-087160 (2004-10-01), None
patent: WO 2005-040205 (2005-05-01), None
patent: WO 2005-058294 (2005-06-01), None
Aitken JF et al., Suppression by polycyclic compounds of the conversion of human amylin into insoluble amyloid. Biochem J. Sep. 15, 2003 15;374(Pt 3):779-84.
Allen, K.G D. et al. (Jan. 1987). “Tetramine Cupruretic Agents: a Comparison in Dogs”, Am. J. Vet. Res. 48(1)28-30.
American Diabetes Association. (1997). “Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus”, Diabetes Care 20:1183.
American Diabetes Association. (1998). “Economic Consequences of Diabetes Mellitus in the U.S. in 1997”, Diabetes Care 21(2):296-309.
Anaja, (1997). “Diagnostic performance of red cell sorbitol assay in a Nigerian teaching hospital”, Clinica Chimica Acta. 262:1.
Appelbaum et al., “The Protective Role of Neocuproine Against Cardiac Damage in Isolated Perfused Rat Hearts”,Free Radical Biology&Medicine, vol. 6, pp. 133-143, 1990: Pargamon Press USA.
Armbruster D A: “Fructosamine Structure Analysis and Clinical Usefulness” Clinical Chemistry, vol. 33, No. 12, 1987, pp. 2153-2163, XP001061531 ISSN: 0009-9147.
Baker, et al. (1993). “Mechanism of fructosamine assay: evdence against role of superoxide as intermediate in nitroblue tetrazollum reduction”. Clin Chem, 39(12):2460.
Barthelmebs, M. at el. (1990). “L-Dopa and Streptozotocin-Induced Diabetic Nephropathy in Rats”,American Journal of Hypertension3(6) Part 2:72S-74S.
Barthelmebs, M. et al. (1991). “Effects of Dopamine Pro-drugs and Fenoldopam on Glomerular Hyperfiltration in Streptozotocin-Induced Diabetes in Rats”,Journal of Cardiovascular Pharmacology18(2)243-253.
Barthelmebs, M. et al. (1995). “Pathophysiological Role of Dopamine in the Kidney: Effects in Diabetes Mellitus and after Contralateral Nephrectomey”,Hypertens. Res. 18(Suppl. I):S131-S136.
Baynes, J.W. (1991). “Role of Oxidative Stress in Development of Complications in Diabetes”, Diabetes 40:405-412.
Berenshtein et al., “Roles of Ferritin and Iron in Ischemic Preconditioning of the Heart”,Molecular and Cellular Biochemistry, 234/235: 283-292, 2002: Kluwer Academic Publishers, Netherlands.
Beshgetoor et al., “Clinical conditions altering cooper metabolism in humans”, Am J Clin Nutr 1998; 67 (suppl):1017S-21S.
Bingham et al., “Characterization of Intracellular copper pools in rat hepatocytes using the chelator diamsar”, Am. J. Physiol. 272 (Gastrointest. Liver Physiol. 35): G1400-G1407, 1997.
Boiadzhieva, N. (1990) -“The Effect of Dopaminergic Pharmocological Agents on the Pancreatic Islet Apparatus in Rats”.Eksp Med Morfol29(3):20-26. (English abstract).
Borgstrom, L. et el. (1986). “Pharmacokinetics of N-Acetylcysteine in Man”,Eur J Clin Pharmacol31:217-222.
Borthwick. T.R. et al. (Apr. 1980). “Copper Chelating Agents: A Comparison of Copruretic Responses to Various Tetramines and D-Penicillamine”, J. Lab. Clin. Med. 95(4):575-580.
Brem S.: ‘Angiogenesis and Cancer Control: From Concept to Therapeutic Trial’ CANCER CONTROL vol. 6, No. 5, Oct. 1999, pp. 438-448.
Brownlee et al., “Aminoguanidine Prevents Diabetes-Induced Arterial Wall Protein Cross-Linking”, Science, New Series, vol. 232. No. 4758 (Jun. 27. 1986), 1629-1632.
Bryszewska et al., “Oxidative Processes In Red Blood Cells from Normal and Diabetic Individuals”,Biochemistry and Molecular Biology International, vol. 37. No. 2, 345-354, Oct. 1995.
Buchanan CM et al., Preptin derived from proInsulin-like growth factor II (proIGF-II) is secreted from pancreatic istet beta-cells and enhances insulin secretion, Blochem J.

Affiliated with

Also associated with

Rating

Treatment of diabetes with copper binding compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of diabetes with copper binding compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of diabetes with copper binding compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2731465